Advances in P-glycoprotein-based approaches for delivering anticancer drugs: pharmacokinetic perspective and clinical relevance

Bibliography

• Bansal T, Jaggi M, Khar R, Talegaonkar S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci 2009;12(1):46-78
   PubMed Web of Science ®Google Scholar
• Parhi P, Mohanty C, Sahoo SK. Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. Drug Discov Today 2012;17(17-18):1044-52
   PubMed Web of Science ®Google Scholar
• Bansal T, Akhtar N, Jaggi M, et al. Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov Today 2009;14(21):1067-74
   PubMed Web of Science ®Google Scholar
• Nakanishi T. Drug transporters as targets for cancer chemotherapy. Cancer Genomics Proteomics 2007;4(3):241-54
   PubMedGoogle Scholar
• Montesinos RN, Beduneau A, Pellequer Y, Lamprecht A. Delivery of P-glycoprotein substrates using chemosensitizers and nanotechnology for selective and efficient therapeutic outcomes. J Control Release 2012;161:50-61
   PubMed Web of Science ®Google Scholar
• Murakami T, Takano M. Intestinal efflux transporters and drug absorption. Expert Opin Drug Metab Toxicol 2008;4(7):923-39
   PubMed Web of Science ®Google Scholar
• Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455(1):152-62
   PubMed Web of Science ®Google Scholar
• Darby RAJ, Callaghan R, McMahon RM. P-glycoprotein Inhibition: the Past, the Present and the Future. Curr Drug Metab 2011;12:722-31
   PubMed Web of Science ®Google Scholar
• Martin C, Berridge G, Higgins C, et al. Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 2000;58(3):624-32
   PubMed Web of Science ®Google Scholar
• Chen L, Li Y, Yu H, et al. Computational models for predicting substrates or inhibitors of P-glycoprotein. Drug Discov Today 2011;17(7):343-51
   PubMed Web of Science ®Google Scholar
• Colabufo NA, Berardi F, Cantore M, et al. Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological, and diagnostic potentials. J Med Chem 2010;53(5):1883
   PubMed Web of Science ®Google Scholar
• Palmeira A, Sousa E, Vasconcelos MH, Pinto MM. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem 2012;19(13):1946-2025
   PubMed Web of Science ®Google Scholar
• Desai PP, Date AA, Patravale VB. Overcoming poor oral bioavailability using nanoparticle formulations - opportunities and limitations. Drug Discov Today Technol 2011;9(2):e87-95
   Google Scholar
• Patel NR, Rathi A, Mongayt D, Torchilin VP. Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int J Pharm 2011;416(1):296-9
   PubMed Web of Science ®Google Scholar
• Wong HL, Bendayan R, Rauth AM, Wu XY. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J Control Release 2006;116(3):275-84
   PubMed Web of Science ®Google Scholar
• Wang JC, Liu XY, Lu WL, et al. Pharmacokinetics of intravenously administered stealth liposomal doxorubicin modulated with verapamil in rats. Eur J Pharm Biopharm 2006;62(1):44-51
   PubMed Web of Science ®Google Scholar
• Varma MVS, Ashokraj Y, Dey CS, Panchagnula R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 2003;48(4):347-59
   PubMed Web of Science ®Google Scholar
• Binkhathlan Z, Lavasanifar A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr Cancer Drug Targets 2013;13(3):326-46
   PubMed Web of Science ®Google Scholar
• Aller SG, Yu J, Ward A, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009;323(5922):1718-22
   PubMed Web of Science ®Google Scholar
• Stenham DR, Campbell JD, Sansom MSP, et al. An atomic detail model for the human ATP binding cassette transporter P-glycoprotein derived from disulfide cross-linking and homology modeling. FASEB J 2003;17(15):2287-9
   PubMedGoogle Scholar
• Becker JP, Depret Gg, Van Bambeke Fo, et al. Molecular models of human P-glycoprotein in two different catalytic states. BMC Struct Biol 2009;9(1):3
   PubMedGoogle Scholar
• Pajeva IK, Globisch C, Wiese M. Structure-function relationships of multidrug resistance P-glycoprotein. J Med Chem 2004;47(10):2523-33
   PubMed Web of Science ®Google Scholar
• Jin MS, Oldham ML, Zhang Q, Chen J. Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans. Nature 2012;490(7421):566-9
   PubMed Web of Science ®Google Scholar
• Ward AB, Szewczyk P, Grimard V, et al. Structures of P-glycoprotein reveal its conformational flexibility and an epitope on the nucleotide-binding domain. Proc Natl Acad Sci USA 2013;110(33):13386-91
   PubMed Web of Science ®Google Scholar
• Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004;75(1):13-33
   PubMed Web of Science ®Google Scholar
• Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003;22(47):7468-85
   PubMed Web of Science ®Google Scholar
• Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84(21):7735-8
   PubMed Web of Science ®Google Scholar
• Ana F, Gilberto A, Falcao A. In vitro and in vivo relevance of the P-glycoprotein probe substrates in drug discovery and development: focus on rhodamine 123, digoxin and talinolol. J Bioequ Bioavail 2011;2:1-23
   Google Scholar
• Dietrich CG, Geier A, Elferink RPJO. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 2003;52(12):1788-95
   PubMed Web of Science ®Google Scholar
• Shukla S, Ohnuma S, Ambudkar SV. Improving cancer chemotherapy with modulators of ABC drug transporters. Curr Drug Targets 2011;12(5):621-30
   PubMed Web of Science ®Google Scholar
• Schellens JHM, Schinkel AH. Method of improving bioavailability of orally administered drugs, a method of screening for enhancers of such bioavailability and novel pharmaceutical compositions for oral delivery of drugs. US7030132; 2006
   Google Scholar
• Broder S, Duchin KL, Selim S. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents. US6245805B1; 1996
   Google Scholar
• Broder S, Duchin KL, Selim S. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents. US7041640B2; 2004
   Google Scholar
• Terwogt JMM, Beijnen JH, ten Bokkel Huinink WW, et al. Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet 1998;352(9124):285
   Web of Science ®Google Scholar
• Van Asperen J, Van Tellingen O, Sparreboom A, et al. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 1997;76(9):1181
   PubMed Web of Science ®Google Scholar
• Chiou WL, Wu TC, Ma C, Jeong HY. Enhanced oral bioavailability of docetaxel by coadministration of cyclosporine: quantitation and role of P-glycoprotein. J Clin Oncol 2002;20(7):1951-2
   PubMed Web of Science ®Google Scholar
• Malingre MM, Richel DJ, Beijnen JH, et al. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol 2001;19(4):1160-6
   PubMed Web of Science ®Google Scholar
• McEntee M, Silverman JA, Rassnick K, et al. Enhanced bioavailability of oral docetaxel by co-administration of cyclosporin A in dogs and rats. Vet Comp Oncol 2003;1(2):105-12
   PubMedGoogle Scholar
• Liscovitch M, Lavie Y. Cancer multidrug resistance: a review of recent drug discovery research. IDrugs 2002;5(4):349-55
   PubMedGoogle Scholar
• Lhomme C, Joly F, Walker JL, et al. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol 2008;26(16):2674-82
   PubMed Web of Science ®Google Scholar
• Friedenberg WR, Rue M, Blood EA, et al. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95). Cancer 2006;106(4):830-8
   PubMed Web of Science ®Google Scholar
• Rago RP, Einstein Jr A, Lush R, et al. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Cancer Chemother Pharmacol 2003;51(4):297-305
   PubMed Web of Science ®Google Scholar
• Seiden MV, Swenerton KD, Matulonis U, et al. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol 2002;86(3):302-10
   PubMed Web of Science ®Google Scholar
• Hyafil Fo, Vergely C, Du Vignaud P, Grand Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993;53(19):4595-602
   PubMed Web of Science ®Google Scholar
• Dantzig AH, Shepard RL, Cao J, et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 1996;56(18):4171-9
   PubMed Web of Science ®Google Scholar
• Oostendorp RL, Buckle T, Beijnen JH, et al. The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs 2009;27(1):31-40
   PubMed Web of Science ®Google Scholar
• Bihorel Sb, Camenisch G, Lemaire M, Scherrmann JM. Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Pharm Res 2007;24(9):1720-8
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Planting AST, Jewell RC, et al. Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Anticancer drugs 1999;10(8):719-28
   PubMed Web of Science ®Google Scholar
• Malingre MM, Beijnen JH, Rosing H, et al. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer 2001;84(1):42-7
   PubMed Web of Science ®Google Scholar
• Kuppens I, Bosch TM, Van Maanen MJ, et al. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Cancer Chemother Pharmacol 2005;55(1):72-8
   PubMed Web of Science ®Google Scholar
• Wu CP, Ohnuma S, Ambudkar SV. Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol 2011;12(4):609-20
   PubMed Web of Science ®Google Scholar
• Najar IA, Sharma SC, Singh GD, et al. Involvement of P-glycoprotein and CYP 3A4 in the enhancement of etoposide bioavailability by a piperine analogue. Chem Biol Interact 2011;190(2):84-90
   PubMed Web of Science ®Google Scholar
• Sachin BS, Najar IA, Sharma SC, et al. Simultaneous determination of etoposide and a piperine analogue (PA-1) by UPLC-qTOF-MS: evidence that PA-1 enhances the oral bioavailability of etoposide in mice. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878(9):823-30
   PubMed Web of Science ®Google Scholar
• Buggins TR, Dickinson PA, Taylor G. The effects of pharmaceutical excipients on drug disposition. Adv Drug Deliv Rev 2007;59(15):1482-503
   PubMed Web of Science ®Google Scholar
• Lo YL. Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. J Control Release 2003;90:37-48
   PubMed Web of Science ®Google Scholar
• Zhang H, Yao M, Morrison AR, et al. Commonly used surfactant, tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats. Arch Pharm Res 2003;26(9):768-72
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Kabanov AV. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release 2008;130(2):98-106
   PubMed Web of Science ®Google Scholar
• Collnot EM, Baldes C, Schaefer UF, et al. Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access. Mol Pharm 2010;7(3):642-51
   PubMed Web of Science ®Google Scholar
• Varma MVS, Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci 2005;25:445-53
   PubMed Web of Science ®Google Scholar
• Akhtar N, Ahad A, Khar RK, et al. The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review. Expert Opin Ther Pat 2011;21(4):561-76
   PubMed Web of Science ®Google Scholar
• Thanki K, Gangwal R, Sangamwar AT, Jain S. Oral delivery of anticancer drugs: challenges and opportunities. J Control Release 2013;170(1):15-40
   PubMed Web of Science ®Google Scholar
• Wiwattanapatapee R, Carreno-Gomez B, Malik N, et al. Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: a potential oral delivery system? Pharm Res 2000;17(8):991-8
   PubMed Web of Science ®Google Scholar
• Constantinides PP, Wasan KM. Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/In vivo case studies. J Pharm Sci 2007;96(2):235-48
   PubMed Web of Science ®Google Scholar
• Binkhathlan Z, Hamdy AD, Brocks RD, Lavasanifar A. Development of a polymeric micellar formulation for valspodar and assessment of its pharmacokinetics in rat. Eur J Pharm Biopharm 2010;75(2):90-5
   PubMed Web of Science ®Google Scholar
• Sane R, Mittapalli KR, Elmquist FW. Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability. J Pharm Sci 2013;102:1343-54
   PubMed Web of Science ®Google Scholar
• Park JH, Park JH, Hur HJ, et al. Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats. Eur J Pharm Sci 2012;45(3):296-301
   PubMed Web of Science ®Google Scholar
• Gao P, Rush BD, Pfund WP, et al. Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J Pharm Sci 2003;92(12):2386-98
   PubMed Web of Science ®Google Scholar
• Wong MY, Chiu GNC. Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model. Nanomedicine 2011;7(6):834-40
   PubMed Web of Science ®Google Scholar
• Misra R, Sahoo SK. Coformulation of doxorubicin and curcumin in poly (D, L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol Pharm 2011;8(3):852-66
   PubMed Web of Science ®Google Scholar
• Duan J, Mansour HM, Zhang Y, et al. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly (butyl cyanoacrylate) nanoparticles. Int J Pharm 2012;426(1):193-201
   PubMedGoogle Scholar
• Patil Y, Sadhukha T, Ma L, Panyam J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release 2009;136(1):21-9
   PubMed Web of Science ®Google Scholar
• Song XR, Cai Z, Zheng Y, et al. Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur J Pharm Sci 2009;37(3):300-5
   PubMed Web of Science ®Google Scholar
• Abbasi M, Lavasanifar A, Uludag H. Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer. Med Res Rev 2013;33(1):33-53
   PubMed Web of Science ®Google Scholar
• Szakacs G, Varadi A, Ozvegy Laczka C, Sarkadi B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today 2008;13(9):379-93
   PubMed Web of Science ®Google Scholar
• Chang JH, Uchizono JA, Park MS. Efflux of drugs via transporters - The anti-absorption pathway. Hu M, Li X, editors. Oral bioavailability: basic principles, advanced concepts, and applications. John Wiley & Sons, Inc; Hoboken, NJ, USA: 2011. p. 111-26
   Google Scholar
• Fletcher JI, Haber M, Henderson MJ, Norris MD. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 2010;10(2):147-56
   PubMed Web of Science ®Google Scholar
• Mazzaferro S, Bouchemal K, Ponchel G. Oral delivery of anticancer drugs III: formulation using drug delivery systems. Drug Discov Today 2013;18(1-2):99-104
   PubMed Web of Science ®Google Scholar
• Eichhorn T, Efferth T. P-glycoprotein and its inhibition in tumors by phytochemicals derived from Chinese herbs. J Ethnopharmacol 2012;141(2):557-70
   PubMed Web of Science ®Google Scholar
• Choi JS, Piao YJ, Kang KW. Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin. Arch Pharm Res 2011;34(4):607-13
   PubMed Web of Science ®Google Scholar
• Shin SC, Li C, Choi JS. Effects of baicalein, an antioxidant, on the bioavailability of doxorubicin in rats: possible role of P-glycoprotein inhibition by baicalein. Pharmazie 2009;64(9):579-83
   PubMed Web of Science ®Google Scholar
• Choi SJ, Shin SC, Choi JS. Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in Rats: possible role of CYP3A4 and P-glycoprotein inhibition by myricetin. Arch Pharm Res 2011;34(2):309-15
   PubMed Web of Science ®Google Scholar
• Lee CK, Ki SH, Choi JS. Effects of oral curcumin on the pharmacokinetics of intravenous and oral etoposide in rats: possible role of intestinal CYP3A and P-gp inhibition by curcumin. Biopharm Drug Dispos 2011;32(4):245-51
   PubMed Web of Science ®Google Scholar
• Li X, Yun JK, Choi JS. Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos 2007;28(3):151-6
   PubMed Web of Science ®Google Scholar
• Li C, Li X, Choi JS. Enhanced bioavailability of etoposide after oral or intravenous administration of etoposide with kaempferol in rats. Arch Pharm Res 2009;32(1):133-8
   PubMed Web of Science ®Google Scholar
• Li X, Choi JS. Effects of quercetin on the pharmacokinetics of Etoposide after oral or intravenous administration of etoposide in rats. Anticancer Res 2009;29(4):1411-15
   PubMed Web of Science ®Google Scholar
• Yang LQ, Wang B, Gan H, et al. Enhanced oral bioavailability and anti-tumour effect of paclitaxel by 20 (s)-ginsenoside Rg3 in vivo. Biopharm Drug Dispos 2012;33(8):425-36
   PubMed Web of Science ®Google Scholar
• Lee CK, Choi JS. Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats. Pharmacology 2010;85(6):350-6
   PubMed Web of Science ®Google Scholar
• Peng SX, Ritchie DM, Cousineau M, et al. Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A. J Pharm Sci 2006;95(9):1984-93
   PubMed Web of Science ®Google Scholar
• Ganta S, Devalapally H, Amiji M. Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation. J Pharm Sci 2010;99(11):4630-41
   PubMed Web of Science ®Google Scholar
• Jin J, Bi H, Hu J, et al. Enhancement of oral bioavailability of paclitaxel after oral administration of Schisandrol B in rats. Biopharm Drug Dispos 2010;31(4):264-8
   PubMed Web of Science ®Google Scholar
• Lim SC, Choi JS. Effects of naringin on the pharmacokinetics of intravenous paclitaxel in rats. Biopharm Drug Dispos 2006;27(9):443-7
   PubMed Web of Science ®Google Scholar
• Kim C-S, Choi S-J, Park C-Y, et al. Effects of silybinin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen in rats. Anticancer Res 2010;30(1):79-85
   PubMed Web of Science ®Google Scholar
• Li C, Kim M, Choi H, Choi J. Effects of baicalein on the pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats: possible role of cytochrome p450 3A4 and P-glycoprotein inhibition by baicalein. Arch Pharm Res 2011;34(11):1965-72
   PubMed Web of Science ®Google Scholar
• Li C, Lim S-C, Kim J, Choi J-S. Effects of myricetin, an anticancer compound, on the bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats. Eur J Drug Metab Pharmacokinet 2011;36(3):175-82
   PubMed Web of Science ®Google Scholar
• Bansal T, Awasthi A, Jaggi M, et al. Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of P-glycoprotein. Life Sci 2008;83(7):250-9
   PubMed Web of Science ®Google Scholar
• Lin L-C, Wang M-N, Tsai T-H. Food-drug interaction of (-) - epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38. Chem Biol Interact 2008;174(3):177-82
   PubMed Web of Science ®Google Scholar
• Hu K, Cao S, Hu F, Feng J. Enhanced oral bioavailability of docetaxel by lecithin nanoparticles: preparation, in vitro, and in vivo evaluation. Int J Nanomedicine 2012;7:3537-45
   PubMed Web of Science ®Google Scholar
• Feng SS, Mei L, Anitha P, et al. Poly (lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel. Biomaterials 2009;30(19):3297
   PubMed Web of Science ®Google Scholar
• Kalaria DR, Sharma G, Beniwal V, Ravi Kumar MN. Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm Res 2009;26(3):492-501
   PubMed Web of Science ®Google Scholar
• Golla K, Cherukuvada B, Ahmed F, Kondapi AK. Efficacy, safety and anticancer activity of protein nanoparticle-based delivery of doxorubicin through intravenous administration in rats. PLoS One 2012;7(12):e51960
   PubMed Web of Science ®Google Scholar
• Ling G, Zhang P, Zhang W, et al. Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition. J Control Release 2010;148(2):241-8
   PubMed Web of Science ®Google Scholar
• Pandita D, Ahuja A, Lather V, et al. Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel. AAPS PharmSciTech 2011;12(2):712-22
   PubMed Web of Science ®Google Scholar
• Zhao L, Feng SS. Enhanced oral bioavailability of paclitaxel formulated in vitamin E - TPGS emulsified nanoparticles of biodegradable polymers: in vitro and in vivo studies. J Pharm Sci 2010;99(8):3552-60
   PubMed Web of Science ®Google Scholar
• Zabaleta V, Ponchel G, Salman H, et al. Oral administration of paclitaxel with pegylated poly (anhydride) nanoparticles: permeability and pharmacokinetic study. Eur J Pharm Biopharm 2012;81(3):514-23
   PubMed Web of Science ®Google Scholar
• Zeng N, Hu Q, Liu Z, et al. Preparation and characterization of paclitaxel-loaded DSPE-PEG-liquid crystalline nanoparticles (LCNPs) for improved bioavailability. Int J Pharm 2012;424(1-2):58-66
   PubMedGoogle Scholar
• Agueros M, Zabaleta V, Espuelas S, et al. Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly (anhydride) nanoparticles. J Control Release 2010;145(1):2-8
   PubMed Web of Science ®Google Scholar
• Jain AK, Swarnakar NK, Godugu C, et al. The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen. Biomaterials 2011;32(2):503-15
   PubMed Web of Science ®Google Scholar
• Zhang T, Chen J, Zhang Y, et al. Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. Eur J Pharm Sci 2011;43(3):174-9
   PubMed Web of Science ®Google Scholar
• Shete H, Chatterjee S, De A, Patravale V. Long chain lipid based tamoxifen nlc. part ii: pharmacokinetic, biodistribution and in vitro anticancer efficacy studies. Int J Pharm 2013;454(1):584-92
   PubMed Web of Science ®Google Scholar
• Jain S, Kumar D, Swarnakar NK, Thanki K. Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. Biomaterials 2012;33:6758-68
   PubMed Web of Science ®Google Scholar
• Dahmani FZ, Yang H, Zhou J, et al. Enhanced oral bioavailability of paclitaxel in pluronic/LHR mixed polymeric micelles: preparation, in vitro and in vivo evaluation. Eur J Pharm Sci 2012;47(1):179-89
   PubMed Web of Science ®Google Scholar
• Mu CF, Balakrishnan P, Cui FD, et al. The effects of mixed MPEG-PLA/Pluronic copolymer micelles on the bioavailability and multidrug resistance of docetaxel. Biomaterials 2010;31(8):2371-9
   PubMed Web of Science ®Google Scholar
• Ke W, Zhao Y, Huang R, et al. Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system. J Pharm Sci 2008;97(6):2208-16
   PubMed Web of Science ®Google Scholar
• Wu Z, Guo D, Deng L, et al. Preparation and evaluation of a self-emulsifying drug delivery system of etoposide-phospholipid complex. Drug Dev Ind Pharm 2011;37(1):103-12
   PubMed Web of Science ®Google Scholar
• Akhtar N, Talegaonkar S, Khar RK, Jaggi M. Self-Nanoemulsifying lipid carrier system for enhancement of oral bioavailability of etoposide by P-glycoprotein modulation: in vitro cell line and in vivo pharmacokinetic investigation. Nanotechnology 2011;9:1-14
   Google Scholar
• Zhang P, Ling G, Sun J, et al. Multifunctional nanoassemblies for vincristine sulfate delivery to overcome multidrug resistance by escaping P-glycoprotein mediated efflux. Biomaterials 2011;32(23):5524-33
   PubMed Web of Science ®Google Scholar
• Nornoo AO, Zheng H, Lopes LB, et al. Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies. Eur J Pharm Biopharm 2009;71(2):310-17
   PubMed Web of Science ®Google Scholar
• Yin YM, Cui FD, Mu CF, et al. Docetaxel microemulsion for enhanced oral bioavailability: Preparation and in vitro and in vivo evaluation. J Control Release 2009;140(2):86-94
   PubMed Web of Science ®Google Scholar
• Kapse SV, Gaikwad RV, Samad A, Devarajan PV. Self nanoprecipitating preconcentrate of tamoxifen citrate for enhanced bioavailability. Int J Pharm 2012;429(1-2):104-12
   PubMedGoogle Scholar
• Torne SJ, Ansari KA, Vavia PR, et al. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges. Drug Deliv 2010;17(6):419-25
   PubMed Web of Science ®Google Scholar
• Cao N, Feng SS. Doxorubicin conjugated to D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation. Biomaterials 2008;29(28):3856-65
   PubMed Web of Science ®Google Scholar
• Anbharasi V, Cao N, Feng SS. Doxorubicin conjugated to D-α-tocopheryl polyethylene glycol succinate and folic acid as a prodrug for targeted chemotherapy. J Biomed Mater Res A 2010;94(3):730-43
   PubMedGoogle Scholar
• Lee E, Lee J, Lee IH, et al. Conjugated chitosan as a novel platform for oral delivery of paclitaxel. J Med Chem 2008;51(20):6442-9
   PubMed Web of Science ®Google Scholar
• Lu Y, Park K. Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. Int J Pharm 2013;453(1):198-214
   PubMed Web of Science ®Google Scholar
• Bourzac K. Nanotechnology: carrying drugs. Nature 2012;491(7425):S58-60
   PubMed Web of Science ®Google Scholar
• Wang R, Billone PS, Mullett WM. Nanomedicine in action: an overview of cancer nanomedicine on the market and in clinical trials. J Nanomater 2013;2013:1-12
   Web of Science ®Google Scholar
• Yarmolenko P, Zhao Y, Landon C, et al. Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours. Int J Hyperthermia 2010;26(5):485-98
   PubMed Web of Science ®Google Scholar
• Janoff A, Mayer L, Redman J, Swenson C. Fixed ratio drug combination treatments for solid tumors. US7842676B2; 2010
   Google Scholar